TY - JOUR T1 - The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab JF - Anticancer Research JO - Anticancer Res SP - 3131 LP - 3137 DO - 10.21873/anticanres.15098 VL - 41 IS - 6 AU - HIDEKAZU KURAMOCHI AU - TAKESHI YAMADA AU - YOICHIRO YOSHIDA AU - AKIHISA MATSUDA AU - HIROHIKO KAMIYAMA AU - CHIHIRO KOSUGI AU - KEIICHIRO ISHIBASHI AU - ATSUKO FUKAZAWA AU - KEISUKE IHARA AU - HIROMICHI SONODA AU - KAZUHIKO YOSHIMATSU AU - HIROSHI YOSHIDA AU - SUGURU HASEGAWA AU - KAZUHIRO SAKAMOTO AU - HIDEYUKI ISHIDA AU - KEIJI KODA AU - On behalf of the TAS CC3 Study Group Y1 - 2021/06/01 UR - http://ar.iiarjournals.org/content/41/6/3131.abstract N2 - Background/Aim: Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3rd-line treatment. Patients and Methods: We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc analysis. Results: Receiver operating characteristic curve analyses of the 3 inflammation-based scores versus DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS). Conclusion: The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment. ER -